Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib + Serplulimab + Stereotactic Radiotherapy as Third-Line Therapy for Metastatic Colorectal Cancer
ChiCTR2500115572Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib and serplulimab in colorectal adenocarcinoma (mCRC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
regorafenibserplulimab
03
Conditions
colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR2500115572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115572.